Pharma giants invest $3.8 bn in psychedelics, turning Indigenous healing into a profit‑driven market amid weak regulation
Original framing: “Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal - Reuters” — Reuters (via Google News)
Indigenous peoples have cultivated psychedelic plant medicines—such as psilocybin mushrooms, ayahuasca, and iboga—within holistic worldviews that link individual well‑being to community and ecosystem health. Their knowledge systems include protocols for set, setting, and integration that are often ignored by corporate R&D, which instead isolates active compounds for patenting. Recognising and co‑creating with Indigenous custodians can prevent cultural appropriation and ensure benefit‑sharing, yet current deals rarely embed such safeguards.
The Lilly‑Atai deal exemplifies a systemic convergence of corporate profit motives, regulatory vacuums, and the historic appropriation of Indigenous psychedelic knowledge.
By foregrounding Indigenous epistemologies, historical patterns of biopiracy, and cross‑cultural governance models, we see that equitable therapeutic futures require legally enforceable benefit‑sharing, open‑access research, and regulatory standards that honor set‑setting and integration. Actors ranging from multinational pharma to national health agencies, Indigenous councils, and civil‑society coalitions must coordinate to reshape the market into a commons that safeguards cultural integrity, ecological sustainability, and inclusive health outcomes.